Bryan Keaney

Chief Financial Officer at Lucy Therapeutics

Chief Financial Officer Bryan is a financial executive with over 25 years of experience managing biotechnology companies from the start-up phase through periods of rapid growth into complex publicly traded entities. He is experienced in building systems and infrastructure, successful at fundraising, and was instrumental in three successful IPOs. Bryan has served in senior roles at CombinatoRx, Synta Pharmaceuticals, Shionogi Bioresearch, and held management roles at Genzyme Corporation and Hybritech.


Org chart

No direct reports

Teams


Offices

This person is not in any offices


Lucy Therapeutics

Lucy Therapeutics is offering a differentiated and novel approach to drug discovery by drugging targets associated with early disease pathogenesis. LucyTx’s unique approach recognizes that improvement of mitochondrial function early in disease will lead to disease modification as opposed to late-stage symptomatic treatments being pursued by many others. Mitochondrial improvement effects multiple downstream effectors that are essential to disease initiation and progression. Our targets have been validated as neuroprotective in multiple animal models. Key to our strategy is a novel dosing regimen which will mimic effects known to be protective for both neurological and cardiovascular events implicated in key CNS diseases. LucyTx proposes to focus on the orphan disease Rett Syndrome for a proof of concept; we will also explore applications of our technology to Parkinson’s and other CNS diseases.


Employees

11-50

Links